Sukocheva OA. Resveratrol and pancreatic cancers: Questions and future perspectives. World J Gastrointest Oncol 2025; 17(3): 100342 [DOI: 10.4251/wjgo.v17.i3.100342]
Corresponding Author of This Article
Olga A Sukocheva, PhD, Senior Scientist, Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Port Road, Adelaide 5000, South Australia, Australia. olga.sukocheva@sa.gov.au
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Mar 15, 2025; 17(3): 100342 Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.100342
Resveratrol and pancreatic cancers: Questions and future perspectives
Olga A Sukocheva
Olga A Sukocheva, Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide 5000, South Australia, Australia
Author contributions: Sukocheva OA conceived, designed, and drafted the submitted manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Olga A Sukocheva, PhD, Senior Scientist, Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Port Road, Adelaide 5000, South Australia, Australia. olga.sukocheva@sa.gov.au
Received: August 14, 2024 Revised: November 20, 2024 Accepted: December 4, 2024 Published online: March 15, 2025 Processing time: 184 Days and 10.2 Hours
Abstract
There is still no effective treatment for pancreatic cancer, one of the deadliest malignancies among the gastrointestinal diseases. Jiang et al demonstrated the presence of senescent cancer-associated fibroblasts (CAFs) in pancreatic cancer tissues, supporting the use of CAFs as potential anti-cancer targets. The study indicated that a natural plant-derived compound resveratrol can reverse senescent CAF phenotype and decrease the growth, migration, and invasiveness of pancreatic cancer cells. Notably, the study indicated that resveratrol might be involved in regulating epithelial-to-mesenchymal transition in the tumor microenvironment. This editorial shares insights on the future investigation of resveratrol signaling in cancer cells and the tumor microenvironment, and discusses resveratrol-based treatment perspectives.
Core Tip: A promising new direction for the treatment of pancreatic cancer has been investigated and reported by Jiang et al. Using immunohistochemistry, the authors assessed pancreatic cancer tissues and detected the presence of senescent cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Following this, the authors observed the ability of the natural polyphenolic compound resveratrol to reverse the senescent CAF phenotype and inhibit pancreatic cancer progression in vitro and in vivo. This editorial assesses important aspects of the original article and discusses future perspectives of resveratrol-containing therapy.
